PROOF COVER SHEET

Author(s):	Shicheng Guo, Qi Zhu, Ting Jiang, Rongsheng Wang, Yi Shen, Xiao Zhu, Yan Wang, Fengmin Bai, Qin Ding, Xiaodong Zhou, Guangjie Chen, and Dong Yi He
Article title:	Genome-wide DNA methylation patterns in CD4+ T cells from Chinese Han patients with rheumatoid arthritis
Article no:	IMOR_A_1218595
Enclosures:	1) Query sheet 2) Article proofs

Dear Author,

1. Please check these proofs carefully. It is the responsibility of the corresponding author to check these and approve or amend them. A second proof is not normally provided. Taylor & Francis cannot be held responsible for uncorrected errors, even if introduced during the production process. Once your corrections have been added to the article, it will be considered ready for publication.

Please limit changes at this stage to the correction of errors. You should not make trivial changes, improve prose style, add new material, or delete existing material at this stage. You may be charged if your corrections are excessive (we would not expect corrections to exceed 30 changes).

For detailed guidance on how to check your proofs, please paste this address into a new browser window: ?http://journalauthors.tandf.co.uk/production/checkingproofs.asp

Your PDF proof file has been enabled so that you can comment on the proof directly using Adobe Acrobat. If you wish to do this, please save the file to your hard disk first. For further information on marking corrections using Acrobat, please paste this address into a new browser window: http://journalauthors.tandf.co.uk/production/acrobat.asp

2. Please review the table of contributors below and confirm that the first and last names are structured correctly and that the authors are listed in the correct order of contribution. This check is to ensure that your name will appear correctly online and when the article is indexed.

Sequence	Prefix	Given name(s)	Surname	Suffix
1		Shicheng	Guo	
2		Qi	Zhu	
3		Ting	Jiang	
4		Rongsheng	Wang	
5		Yi	Shen	
6		Xiao	Zhu	
7		Yan	Wang	
8		Fengmin	Bai	
9		Qin	Ding	
10		Xiaodong	Zhou	
11		Guangjie	Chen	
12		Dong Yi	He	

Queries are marked in the margins of the proofs, and you can also click the hyperlinks below.

General points:
1. **Permissions:** You have warranted that you have secured the necessary written permission from the appropriate copyright owner for the reproduction of any text, illustration, or other material in your article. Please see http://journalauthors.tandf.co.uk/permissions/usingThirdPartyMaterial.asp.

2. **Third-party content:** If there is third-party content in your article, please check that the rightsholder details for re-use are shown correctly.

3. **Affiliation:** The corresponding author is responsible for ensuring that address and email details are correct for all the co-authors. Affiliations given in the article should be the affiliation at the time the research was conducted. Please see http://journalauthors.tandf.co.uk/preparation/writing.asp.

4. **Funding:** Was your research for this article funded by a funding agency? If so, please insert 'This work was supported by < insert the name of the funding agency in full >', followed by the grant number in square brackets '[grant number xxxx]'.

5. **Supplemental data and underlying research materials:** Do you wish to include the location of the underlying research materials (e.g. data, samples or models) for your article? If so, please insert this sentence before the reference section: 'The underlying research materials for this article can be accessed at < full link > / description of location [author to complete]'. If your article includes supplemental data, the link will also be provided in this paragraph. See < http://journalauthors.tandf.co.uk/preparation/multimedia.asp > for further explanation of supplemental data and underlying research materials.

6. The **PubMed** (http://www.ncbi.nlm.nih.gov/pubmed) and **CrossRef databases** (www.crossref.org/) have been used to validate the references. Changes resulting from mismatches are tracked in red font.

AUTHOR QUERIES

Q1: Please note that the short title (running head at top of page) has been suggested. Please correct if this is inaccurate.

Q2: Please provide the town and state abbreviation (for the USA) or town and country of origin (for other countries) identifying the headquarters location for all software and instruments mentioned in the article.

Q3: As per journal styleauthor contributions are not allowed, hence it has been deleted. Please check.

Q4: Please note that the journal style use 6 authors et al., for 8 or more authors. Kindly provide the names of all authors if the references have 1 or more authors per journal style.

Q5: Please provide missing volume number and page range for Refs [4] and [32] in references list entry.

Q6: Please provide last page number.

How to make corrections to your proofs using Adobe Acrobat/Reader

Taylor & Francis offers you a choice of options to help you make corrections to your proofs. Your PDF proof file has been enabled so that you can mark up the proof directly using Adobe Acrobat/Reader. This is the simplest and best way for you to ensure that your corrections will be incorporated. If you wish to do this, please follow these instructions:

1. Save the file to your hard disk.

2. Check which version of Adobe Acrobat/Reader you have on your computer. You can do this by clicking on the "Help" tab, and then "About".

If Adobe Reader is not installed, you can get the latest version free from http://get.adobe.com/reader/.

3. If you have Adobe Acrobat/Reader 10 or a later version, click on the "Comment" link at the right-hand side to view the Comments pane.

4. You can then select any text and mark it up for deletion or replacement, or insert new text as needed. Please note that these will clearly be displayed in the Comments pane and secondary annotation is not needed to draw attention to your corrections. If you need to include new sections of text, it is also possible to add a comment to the proofs. To do this, use the Sticky Note tool in the task bar. Please also see our FAQs here: http://journalauthors.tandf.co.uk/production/index.asp.

5. Make sure that you save the file when you close the document before uploading it to CATS using the "Upload File" button on the online correction form. If you have more than one file, please zip them together and then upload the zip file.
If you prefer, you can make your corrections using the CATS online correction form.

Troubleshooting

Acrobat help: http://helpx.adobe.com/acrobat.html
Reader help: http://helpx.adobe.com/reader.html

Please note that full user guides for earlier versions of these programs are available from the Adobe Help pages by clicking on the link "Previous versions" under the "Help and tutorials" heading from the relevant link above. Commenting functionality is available from Adobe Reader 8.0 onwards and from Adobe Acrobat 7.0 onwards.

Firefox users: Firefox's inbuilt PDF Viewer is set to the default; please see the following for instructions on how to use this and download the PDF to your hard drive: http://support.mozilla.org/en-US/kb/view-pdf-files-firefox-without-downloading-them#w_using-a-pdf-reader-plugin

ORIGINAL ARTICLE

Genome-wide DNA methylation patterns in CD4+ T cells from Chinese Han patients with rheumatoid arthritis

Shicheng Guo[1]†, Qi Zhu[1]†, Ting Jiang[1,2]†, Rongsheng Wang[1,2], Yi Shen[1,2], Xiao Zhu[3], Yan Wang[1], Fengmin Bai[1,2], Qin Ding[1,2], Xiaodong Zhou[4], Guangjie Chen[5], and Dong Yi He[1,2]

[1]Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional and Western Medicine, Shanghai, China, [2]Arthritis Institute of Integrated Traditional and Western Medicine, Shanghai Chinese Medicine Research Institute, Shanghai, China, [3]Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China, [4]University of Texas Medical School at Houston, Houston, TX, USA, and [5]Department of Immunology and Microbiology, Shanghai JiaoTong UniversitySchool of Medicine, Shanghai, China

Abstract

Introduction: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Recent evidence indicated the epigenetic changes may contribute to the pathogenesis of RA.

Method: To understand the extent and nature of dysregulated DNA methylation in RA CD4T cells, we performed a genome-wide DNA methylation study in CD4 + T cells in 12 RA patients compared to 12 matched normal healthy controls. Cytosine methylation status was quantified with Illumina methylation 450K microarray.

Result: The DNA methylation profiling showed 383 hyper- and 785 hypo-methylated genes in the CD4 + T cells of the RA patients ($p < 3.4 \times 10^{-7}$). Gene ontology analysis indicated transcript alternative splicing and protein modification mediated by DNA methylation might play an important role in the pathogenesis of RA. In addition, the result showed that human leukocyte antigen (HLA) region including *HLA-DRB6*, *HLA-DQA1* and *HLA-E* was frequently hypomethylated, but *HLA-DQB1* hypermethylated in CpG island region and hypomethylated in CpG shelf region in RA patients. Outside the MHC region, *HDAC4*, *NXN*, *TBCD* and *TMEM61* were the most hypermethylated genes, while *ITIH3*, *TCN2*, *PRDM16*, *SLC1A5* and *GALNT9* are the most hypomethylated genes.

Conclusion: Genome-wide DNA methylation profile revealed significant DNA methylation change in CD4 + T cells from patients with RA.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues and therefore causes chronic inflammation of the joints. Autoimmune diseases cause the body's immune system to mistake its own tissues for foreign invaders. About 0.5–1% of the population in the world are effected by RA [1] and the corresponding economic burden is heavy all over the world.

In the past decades, the etiopathogenesis of RA has been widely exploited. The most important etiological source of RA comes from single nucleotide polymorphisms (SNPs). Genome-wide association studies (GWAS) based on SNPs have identified multiple SNPs which were believed to be significantly associated

with RA [2,3]. However, as demonstrated in our previous work, even for high familial risk disease as thyroid cancer, a few of the significant SNPs could just have limited prediction power [4]. As expected, large number of copy number variations were then demonstrated to be significantly associated with the susceptibility to RA [5,6]. The accumulating evidences from the genetics showed the systemic autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE), gout and systemic Sclerosis (SSc), usually shared some clinical characteristics and genetic risk factors. Therefore, theoretically, these complex diseases might share some analogous defects in the level of epigenome.

The current estimated heritability of RA is about 20–50% and is significantly different between RA patients with and without anti-citrullinated protein antibody [7], which indicates that the epigenetic factors play more important roles in the etiology of RA. In addition, genome-wide DNA methylation of SLE [8,9] and SjS [10] have showed that large number of DNA methylation were changed in the CD4 + or CD8 + T-cells in the patients. Therefore, it could be postulated that DNA methylation would also be significantly involved in the pathogenesis of RA. DNA methylation is one of the most important epigenetic modifications. Our previous study showed that DNA methylation played an important

†These authors contributed equally to the study.
Correspondence to: Dong Yi He, Department of Rheumatology, Guanghua Integrative Medicine Hospital, Changning District, Shanghai 200052, China. Tel: +86-21-55664885. Fax: +86-21-55664885. E-mail: dongyihe@medmail.com.cn
Guangjie Chen, Department of Immunology and Microbiology, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China. Tel: +86-21-63846590. E-mail: guangjie_chen@163.com

role in gene [11] and microRNA [12] expression regulation, cancer initiation/progress, and therefore has an important role in the cancer diagnosis [13,14] and prognosis.

Previous studies suggested several important immune-related genes were aberrantly methylated in RA genome [15–18]. However, the genome-wide DNA methylation profile of RA patient was still very limited, especially in Asian population and cannot be accessed publically. It created big problem for the candidate gene-based research to discover more RA-related DNA methylation regions and identify missing heritability of RA. Considering the evidence that treatment with monoclonal antibodies against the CD4 antigen leads to immunomodulation would significantly result in clinical benefits for RA patients [19], in the present study, we conducted an investigation of the genome-wide DNA methylation profiles in the CD4 + T-cells of 12 RA and matched 12 healthy individuals.

Methods

Patients and controls

Twelve RA patients and 12 rigorously matched controls were studied, such as gender, age (Table 1). All the samples that we collected were non-smokers and were first diagnosed RA patients without long-term medicine therapy. The mean age was 42.83 in patients and 43.75 in controls without significant difference ($p = 0.95$). All patients fulfilled the American College of Rheumatology classification criteria for RA. The research was approved by academic advisory board of Guanghua Hospital. Clinical data were collected at the time of sample collection. IgG class anti-CCP antibody was measured using ELISA kit (AESKULISA CCP, Germany). RF was measured by Siemen-s Dade Behring BN II Nephelometer. Erythrocyte sedimentation rate (ESR) was achieved by Monitor-100 (VITAL DIAGNOSITICS, Italia) with routine test standards from the hospital laboratory.

Isolation of PBMCs and CD4 + T cells

Mononuclear cells (PBMCs) were prepared from blood specimens of RA and normal samples by Ficoll–Hypaque centrifugation (Amersham Biosciences) using the standard protocol, and immediately processed for cell culture [20]. CD4 + T cells were prepared from freshly isolated PBMCs by depleting cells expressing CD8, CD14, CD16, CD19, CD36, CD56, CD123, γ/δ T-cell receptors, and glycophorin A using No-Touch T cell isolation kits (MiltenyiBiotec). The purity of the CD4 + T cells was 95–98%, as determined by flow cytometry being stained with

Percp cy5.5-conjugated anti-human CD4 (BD Pharmingen, San Diego, CA). Whole genomic DNA was then prepared using a Qiagen DNEasy kit (Qiagen, Germantown, MD) and bisulfite-treated using a Zymo EZ DNA Methylation Kit (Zymo, Orange, CA).

Illumina infinium human methylation 450

Bisulfite-converted patient and control DNA samples were prepared and quantified using a NanoDrop scanning spectrophotometer (Thermo, Wilmington, DE). For each sample, 500 ng of whole-genome bisulfite-converted DNA was denatured, fragmented, amplified and methylation signals were detected by Infinium HumanMethylation450K BeadChip (Illumina, San Diego, CA).

Standard DNA methylation 450K analysis pipeline (SMAP) was implemented to conduct the methylation microarray analysis. Genome Studio (Illumina) was used to generate signal intensities and detect p values with internal control normalization (ICN) and background subtraction (BS). Quality control and normalization were conducted with R package of ''lumi''. Probes with SNPs located in ChrX and ChrY were removed before further analysis. In addition, probes with a detection of p value >0.01 exceeding 5% of the samples were also filtered out while other probes less than 5% of samples were labeled as missing value (NA) to avoid further bias in the following statistic and bioinformatic analysis. Then, the overall signal intensity, the distribution of M-values and the number of significantly detected sites were used to measure the quality of the beadchip. Obvious outlier samples and probes were removed before the differential methylation loci identification. Color-bias adjustment and quantile normalization (QN) were performed on signal intensities with the package of ''lumi''. Finally, beta-mixture quantile normalization (BMIQ) to the β-values were conducted to adjust the bias caused by different types of probes (type I and type II).

Statistical analysis

PCA and Hierarchical cluster analysis were applied to show the correlation between the samples. Two RA samples were filtered since they were obviously different with others in the PCA analysis. Differentially methylated loci were identified by paired t-test based on the beta value of the normalization data. The raw p-values were adjusted by false discovery rate (FDR <0.05) for the multiple test correction. Association between clinical characteristics and differential methylation loci were conducted with linear regression with the significant threshold of 0.005. Gene ontology

Table 1. Characteristic of the enrolled RA and control samples.

SSID	Age	Gender	COD (Year)	RF (IU/mL)	Anti-CCP (RU/ml)	ESR (mm/h)	SJC	TJC	PGA	DAS28-CRP	Control	Age	Gender
RA0001	47	Male	6	<20	158.21	29	4	6	70	5.27	HP0001	47	Male
RA0010	37	Female	0.8	22.2	792.81	14	0	0	10	1.99	HP0010	35	Female
RA0011	52	Male	0.2	2260	104.86	46	10	12	60	6.35	HP0011	52	Male
RA0012	56	Male	1.5	1000	1600	140	10	11	85	7.39	HP0012	56	Male
RA0002	40	Female	3	198	789.54	36	1	1	30	3.77	HP0002	39	Female
RA0003	47	Female	3	152	270.38	140	18	19	90	8.35	HP0003	46	Female
RA0004	23	Female	1.5	<20	71.42	24	3	4	45	4.46	HP0004	23	Female
RA0005	28	Female	11	127	306.09	54	18	18	80	7.48	HP0005	27	Female
RA0006	39	Female	20	<20	<25	66	3	3	50	5.09	HP0006	40	Female
RA0007	25	Female	4	1020	1540.83	23	18	19	55	6.59	HP0007	27	Female
RA0008	57	Female	10	<20	<25	78	3	3	60	5.34	HP0008	57	Female
RA0009	39	Female	15	1200	178.88	75	22	26	70	8.17	HP0009	38	Female

COD: course of a disease, RF: rheumatoid factor; Anti-CCP: anti-cyclic citrullinated peptide antibody; ESR: erythrocyte sedimentation rate; SJC: swollen joint count; TJC: tender joint count; PGA: patient global assessment; DAS28-CRP: disease activity score in 28 Joints.

analysis was conducted with DAVID bioinformatics resources [21]. The interactions among the differential methylated genes were inferred by String (version 10.0) [22]. Human references of GRCh37/hg19 were used in the bioinformatics analysis and result representation. All methods and analyses were performed in R (version 3.2.1). The data were deposited in the Gene Expression Omnibus (GEO accession: GSE71841).

Results

We studied genome-wide CD4 + T-cell DNA methylation in RA patients and controls using a high-throughput method based on bead microarrays that allow simultaneous screening of 482,421 CpG sites spanning the promoter region of 21,231 genes (99% RefSeq genes). Twenty-four biological replicates (12 RA patients and 12 matched healthy controls) were collected and enrolled in the project (Table 1). 1067 probes were removed from the dataset filtered with the detection of p-value above 0.01. Four hundred forty-three probes were removed from the dataset with a bead count <3 in at least 5% of samples. 29,021 probes with SNPs (dbSNP version: 142) were removed to decrease the bias of the analysis. 8510 and 11,245 probes were removed since multiple alignments were located in chromosome X or chromosome Y. Eventually, 435,226 probes were kept in the 24 samples.

In order to make sure the cells in our study were significantly derived from CD4 + T-cell, we projected our methylation signals into the PC1 and PC2 dimension of whole blood cell. The analysis showed our samples were clearly aggregated with CD4 + cells and was estranged with other kinds of cells, such as CD8 + T-cell, CD14+, CD19+, which indicates the samples were successfully prepared in the process of sample collection (Figure 1A). Further, to ensure that differential methylation patterns identified in our study were not influenced by potential differences in T-cell subset populations between RA patients and controls, we detected the methylation profiles of a number of genes known to be related with particular T-cell subsets, such as *IL4*, *IL13* (Th2), *IFNG* (Th1) and *IL17F* (Th17). None of these CpG sites were found to be significantly different between case and control, suggesting no difference in T-cell subsets between RA patients and controls.

Meanwhile, PCA analysis was conducted to our methylation 450K, the result showed PC1 and PC2 explained the total variance of 29.9% and 14%, respectively, while the top 13 principle component could explain as high as 80% variance. These results indicated the information of the data composed by limited informative clinical or demographical signals and our data were creditable for the further bioinformatic and biostatistical analysis (Supplementary Figure 1).

Genome-wide DNA methylation profile of RA

We identified 810 hypo-methylated and 392 hyper-methylated CpG sites in RA CD4 + T cells compared to normal controls, representing 785 and 383 genes which were hypo-methylated and hyper-methylated in RA patients with $p < 3.4 \times 10^{-7}$(paired t-test, FDR <0.05, Supplementary Table 1).

Cluster analysis based on significantly differential methylated loci showed distinct separation between RA and normal controls (Figure 1B). More hypo-methylated CpG site than hyper-methylated CpG site indicated genome-wide hypo-methylation in the genome of RA. Interaction maps of differentially-methylated genes was constructed based on String 10.0 and the result showed these DMGs were highly interacted rather than functionally isolated (Figure 2). Gene ontology analysis showed alternative splicing ($p = 1.2 \times 10^{-7}$, FDR) and phosphoprotein ($p = 1.7 \times 10^{-2}$, FDR) were significantly aberrant in RA patients (Table 2), indicating the abnormal that transcript alternative splicing and protein modification mediated by DNA methylation might play an important role in the pathogenesis of RA. In addition, immune response (p-value $= 3.2 \times 10^{-5}$) and white blood cells monocyte-associated (p-value $= 0.02$) gene ontology was also significantly enriched.

The result showed human leukocyte antigen (HLA) region was frequently hypo-methylated in RA patients, including *HLA-DRB6* ($p = 6.61 \times 10^{-0}$), *HLA-DQA1* ($p = 7.09 \times 10^{-9}$) and *HLA-E* ($p = 3.24 \times 10^{-7}$), however, *HLA-DQB1* showed different methylation profiles with significant hyper-methylation in CpG island region and hypo-methylation in CpG shelf region (Table 3). Outside the MHC region, the most hyper-methylated genes in RA included *HDAC4* ($p = 1.47 \times 10^{-7}$), *NXN* ($p = 5.5 \times 10^{-9}$), *TBCD* ($p = 4.48 \times 10^{-8}$) and *TMEM61* ($p = 1.7 \times 10^{-7}$) while the most significant hypo-methylated genes included *ITIH3* ($p = 1.16 \times 10^{-7}$), *TCN2* ($p = 1.57 \times 10^{-8}$), *PRDM16* ($p = 3.1 \times 10^{-9}$), *SLC1A5* ($p = 2.94 \times 10^{-7}$) and *GALNT9* ($p = 8.26 \times 10^{-9}$).

Figure 1. Genome-wide DNA methylation profile of RA and bioinformatics of differential methylation loci. (A) PCA analysis showed the CD4 + cells from our study were aggregated with CD4 + T-cells from GSE35069, indicating the samples were well prepared. (B) Hierarchical cluster analysis based on differential methylated loci separated samples into RA and control group.

Figure 2. Gene–gene interaction analysis to differential methylated genes. The interaction was inferred by protein–protein interaction database of String 10.

Table 2. Gene ontology analysis to differential methylation genes in RA.

Term	Count	Frequency (%)	p-Value	Fold enrichment	Benjamini
Alternative splicing	415	47.64	2.5×10^{-10}	1.26	1.23191E-07
Splice variant	417	47.87	1.4×10^{-10}	1.27	3.11674E-07
Alternative products	398	45.69	3.7×10^{-8}	1.23	9.31881E-07
Innate *immune* response	52	18.14	4.1×10^{-7}	1.44	3.20146E-05
Regulation of innate immune response	41	11.93	2.7×10^{-5}	1.30	0.001039486
Signaling by Rho GTPases	16	1.84	3.0×10^{-4}	2.88	0.013928772
White blood cells monocyte	72	8.26	1.7×10^{-3}	1.43	0.028321431

Correlation between DNA methylation and disease characteristics

As shown in Table 1, large numbers of clinical characteristics were recorded for our patients. Identifying clinical relevant DNA methylation loci would provide important insight to the pathological mechanism of RA and valuable corresponding clinical application. Association analysis between clinical characteristics and identified differential methylated loci were also conducted (Table 4). We found the methylation levels of *OR5A2* (cg02981094, $p = 2.6 \times 10^{-4}$), *ALDH9A1* (cg03984859, $p = 2.8 \times 10^{-4}$) and *C5orf32* (cg02070114, $p = 2.2 \times 10^{-4}$) were significantly associated with the disease course of RA. In addition, the

methylation level of *ZC3H11A* (cg02337583) was significantly associated with the level of rheumatoid factor in RA patients ($p = 8.9 \times 10^{-4}$). The methylation level of *OAS2* (cg00085448) was significantly associated with the PGA in RA patients ($p = 4.1 \times 10^{-4}$). Furthermore, *C16orf71* (cg04705084), *LOC100129716* (cg00598143) and miR-762 (cg02558026) were found to be significantly associated with DAS28-CRP with p-values of 5.8×10^{-3}, 5.2×10^{-3}, and 7.5×10^{-3}, respectively. Five loci which included *SLC38A8* (cg01740650, $p = 3.0 \times 10^{-3}$), *C18orf19* (cg00448482, $p = 3.0 \times 10^{-3}$), *COL18A1* (cg04760448, $p = 1.9 \times 10^{-3}$), *BAT3* (cg05649229, $p = 4.9 \times 10^{-3}$) and *PLD3* (cg07071106, $p = 4.4 \times 10^{-3}$) were significantly associated with ESR. Finally, we found *HSPA12A* (cg06942850) was significantly

Table 3. Differential methylation status of HLA genes in RA.

Gene	CpG site	p-Value	Delta-Beta	Ratio-Beta	Case	Control	Chromosome	CpG Shore	Type
HLA-DOA	cg00540941	4.70×10^{-8}	−0.18	0.65	0.34	0.52	chr6:32974843–32974844	N_Shore	II
HLA-DQA1	cg02919082	7.09×10^{-9}	−0.38	0.44	0.30	0.67	chr6:32605694–32605695	NA	II
HLA-DQA1	cg04054303	9.83×10^{-12}	−0.47	0.40	0.31	0.78	chr6:32606445–32606446	NA	II
HLA-DQB1	cg02902672	1.62×10^{-8}	−0.63	0.18	0.14	0.76	chr6:32635360–32635361	S_Shelf	II
HLA-DQB1	cg04777551	1.44×10^{-8}	−0.46	0.47	0.41	0.87	chr6:32628953–32628954	N_Shelf	II
HLA-DQB2	cg02964065	1.99×10^{-7}	0.08	1.11	0.77	0.69	chr6:32729545–32729546	Island	I
HLA-DRB1	cg00211215	1.60×10^{-7}	0.66	3.39	0.94	0.28	chr6:32552246–32552247	Island	I
HLA-DRB1	cg04026937	1.60×10^{-10}	−0.62	0.08	0.05	0.66	chr6:32549361–32549362	N_Shelf	II
HLA-DRB1	cg06032479	3.67×10^{-8}	0.20	1.27	0.92	0.73	chr6:32552026–32552027	Island	I
HLA-DRB1	cg06204447	4.05×10^{-8}	−0.18	0.76	0.57	0.74	chr6:32546665–32546666	NA	II
HLA-DRB6	cg00103771	6.61×10^{-10}	−0.64	0.24	0.20	0.84	chr6:32525805–32525806	NA	II
HLA-DRB6	cg04688450	5.38×10^{-9}	−0.34	0.44	0.27	0.62	chr6:32526366–32526367	NA	II
HLA-DRB6	cg06559318	1.17×10^{-8}	−0.82	0.05	0.04	0.85	chr6:32526260–32526261	NA	I
HLA-E	cg02678305	4.74×10^{-8}	−0.05	0.89	0.39	0.43	chr6:30460322–30460323	S_Shelf	II
HLA-E	cg03725115	3.24×10^{-7}	−0.02	0.72	0.05	0.07	chr6:30458102–30458103	Island	I

Deta-beta represent the difference between RA and controls. Ratio-beta represent the fold-change of the average methylation level in RA compared with controls.

Table 4. Clinical characteristics associated methylation loci identified by HM450K in RA.

	Gene Symbol	CpG Loci	p-Value
Disease course	OR5A2	cg02981094	2.6×10^{-4}
	ALDH9A1	cg03984859	2.8×10^{-4}
	C5orf32	cg02070114	2.2×10^{-4}
Rheumatoid factor	ZC3H11A	cg02337583	8.9×10^{-4}
Patient global assessment	OAS2	cg00085448	4.1×10^{-4}
DAS28-CRP	C16orf71	cg04705084	5.8×10^{-3}
	LOC100129716	cg00598143	5.2×10^{-3}
	miR-762	cg02558026	7.5×10^{-3}
ESR	SLC38A8	cg01740650	3.0×10^{-3}
	C18orf19	cg00448482	3.0×10^{-3}
	COL18A1	cg04760448	1.9×10^{-3}
	BAT3	cg05649229	4.9×10^{-3}
	PLD3	cg07071106	4.4×10^{-3}
Tender joint count	HSPA12A	cg06942850	3.2×10^{-3}

associated with tender joint count (TJC) with a *p*-value of 3.2×10^{-3} (Table 4).

Discussion

In summary, we profiled the genome-wide DNA methylation changes of the CD4 + T-cell in the RA patients of Han Chinese with Illumina methylation 450K microarray. Based on stringent measurement and analysis, 1202 CpG loci showed significant difference in the CD4 + T-cells between RA and controls. Gene ontology and interaction analysis showed these genes were functionally related and interacted with each other. The hypo-methylated regions appeared dominant in RA patients, which was consistent with the previous report [23].

Compared with DNA methylation change of cancer which usually contains thousand differential methylated loci, systemic autoimmune rheumatic diseases seems to have only few differential methylation regions. PCA analysis to our methylation dataset also revealed there is no significant separation between RA and control, indicating there would be not many different methylation regions in CD4 + T-cells between RA and normal individual. Jeffries et al. identified 341 differential methylation loci in CD4 + between SLE and health control [24]. Altorok et al. identified 753 differential methylation loci in CD4 + between SjS and health control [10]. Although multiple test correction has been conducted in these papers, we believe, there are still large number of differential methylated loci would be false positive. Therefore, the candidate differential methylated loci underlying the pathogenesis of RA would be limited. Compared with Kazuhisa's study, there are 81 shared differential methylated CpG loci which might be very important in the pathogenesis of RA. More genome-wide DNA methylation profiles from different ethnic populations may provide ethnic specific information of methylation changes of RA patients.

In this study, we did not perform the validation in another independent cohort because previous studies have shown the accuracy of the methylation 450K were very high [25]. We also did not conduct the gene expression analysis because the function of the methylation to the complex disease is seen not only in gene expression but also in some other important functions such as alternative expression [26], genomic stability [27] and interaction with genetic variation such as SNPs [28]. On the other hand, we want to emphasize that the epigenetic mechanism of RA should be paid more precision not only for PBMC [29] but also the subset of the blood cells. In the next step, we would complete the genome-wide methylation profile for CD8+, CD17 + T-cells, etc., in RA to provide epigenetic contribution from each immune-cells. In addition, our data would provide an opportunity to compare the methylation profiles of CD4 + among SLE, gout and other auto-immune diseases. Glossop et al. identified 761 differential methylated CpG loci between RA and normal individuals from Caucasia population [18]. We compared the aberrant different methylation loci between our study and Glossop et al., and found GALNT9 was shared in both studies and GALNT9 was demonstrated to be hypo-methylated in RA patients. Although only one gene was shared in our two studies, we think it is acceptable because the differential methylation loci identified by us and Glossop et al. are only a small subset of the total differential methylation loci because of the small sample size and the low statistic power [18]. Furthermore, the DNA methylation was significantly influenced by large number of genetic, environment exposures and the clinical characteristics of the patients as shown in our study, which might bring some difference between our study and Glossop et al. [18]. The roles of several genes in RA have been widely discovered in the previous studies. Numerous studies have indicated that decreased HDAC activity in patients with RA may contribute to local pro-inflammatory cytokine production and reduce the responses to corticosteroid treatment. Histone deacetylases (HDACs) activity can modify transcription factor activity, prevent expression of pro-apoptotic genes, and therefore terminate transcription following deacetylation of

histones [30]. They have pleiotropic effects within the immune system. At least 11 histone deacetylase (HDAC) exist in human genome and could be divided into four sub-families, including class I (HDAC1,2,3,8), II (HDAC4,5,6,7,9,10), III (Sirtuin 1-7) and IV (HDAC11) on the basis of size, homology, and assembly. HDAC4 belongs to the class IIa HDACs which are predominantly playing the role on regulating adaptive immunity. Previous evidence showed nuclear export of HDAC4 is quite important for induced expression of IL5 in activated T-cells, indicating the methylation status aberrant would cause compressive influence to immune-response. Meanwhile, methylation change of HDACs might also cause isoform-selective difference in immune cells, and therefore caused different response to the corresponding drugs for different RA patients [31]. ITIH3 was demonstrated as one of the powerful biomarkers for RA in the lasted study from Liao et al. [32]. ITIH3 could act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which were essential to cells undergoing biological processes (UniProtKB/Swiss-Prot). In terms of other remaining genes, we still do not have sufficient evidence to show they play significant role in RA pathogenesis and development, including MXN, TBCD, TMEM61, TCN2, PRDM16, and SLC1A5, and therefore they might be novel biomarkers for RA diagnosis and would be helpful on personalized medicine and precision medicine in RA. Our study demonstrates that the epigenetic-based association study or biomarker identification really need large samples in different populations that the shared epigenetic biomarkers could be found eventually.

Conclusion

Genome-wide DNA methylation patterns revealed significant DNA methylation change in CD4 + T cells from patients with RA.

Acknowledgements

Conflict of interest

Authors declare no conflicts of interest.

References

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–61.
2. Acosta-Colman I, et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013;14(7):727–34.
3. Eleftherohorinou H, et al. Pathway-driven gene stability selection of two rheumatoid arthritis GWAS identifies and validates new susceptibility genes in receptor mediated signalling pathways. Hum Mol Genet. 2011;20(17):3494–506.
4. Guo S, Wang YL, Li Y, Jin L, Xiong M, Ji QH, Wang J. Significant SNPs have limited prediction ability for thyroid cancer. Cancer Med. 2014. doi: 10.1002/cam4.211.
5. Song X, et al. Association between HLA-DQA1 gene copy number polymorphisms and susceptibility to rheumatoid arthritis in Chinese Han population. J Genet. 2014;93(1):215–8.
6. Chen JY, et al. Association of FCGR3A and FCGR3B copy number variations with systemic lupus erythematosus and rheumatoid arthritis in Taiwanese patients. Arthritis Rheumatol. 2014;66(11):3113–21.
7. Frisell T, et al. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 2013;65(11):2773–82.
8. Javierre BM, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010;20(2):170–9.
9. Richardson B, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990;33(11):1665–73.
10. Altorok N, et al. Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjogren's syndrome. Arthritis Rheumatol. 2014;66(3):731–9.
11. Wang X, et al. Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers. FASEB J. 2013;27(10):4194–203.
12. He Y, et al. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia. 2011;13(9):841–53.
13. Guo S, et al. Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC). Clin Epigenetics. 2015;7:3.
14. Guo S, et al. Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer. Clin Epigenetics. 2014;6(1):5.
15. Glossop JR, et al. DNA methylation profiling of synovial fluid FLS in rheumatoid arthritis reveals changes common with tissue-derived FLS. Epigenomics 2015;7(4):539–51.
16. Liebling MR. Methylation of the CTLA-4 promoter and Treg cell dysfunction in rheumatoid arthritis: comment on the article by Cribbs et al. Arthritis Rheumatol. 2015;67(5):1406.
17. van Steenbergen HW, et al. Differential methylation within the major histocompatibility complex region in rheumatoid arthritis: a replication study. Rheumatology (Oxford). 2014;53(12):2317–8.
18. Glossop JR, et al. Genome-wide DNA methylation profiling in rheumatoid arthritis identifies disease-associated methylation changes that are distinct to individual T- and B-lymphocyte populations. Epigenetics. 2014;9(9):1228–37.
19. Horneff G, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 1991;34(2):129–40.
20. Chen G, et al. Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum. 2010;62(10):2900–8.
21. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
22. Szklarczyk D, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52.
23. Karouzakis E, et al. Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2012;64(6):1809–17.
24. Jeffries MA, et al. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011;6(5):593–601.
25. Dedeurwaerder S, et al. Evaluation of the infinium methylation 450K technology. Epigenomics. 2011;3(6):771–84.
26. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation. Trends Genet. 2015;31(5):274–80.
27. Rizwana R, Hahn PJ. CpG methylation reduces genomic instability. J Cell Sci. 1999;112(Pt 24):4513–9.
28. Shoemaker R, et al. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res. 2010;20(7):883–9.
29. Liu Y, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013;31(2):142–7.
30. Grabiec AM, Tak PP, Reedquist KA. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of

inflammatory disease: should we keep our HATs on? Arthritis Res Ther. 2008;10(5):226.

31. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.

32. Liao CC, et al. Comparative analysis of novel autoantibody isotypes against citrullinated-inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3) peptide in serum from Taiwanese females with rheumatoid arthritis, primary Sjogren's syndrome and secondary Sjogren's syndrome in rheumatoid arthritis. J Proteomics. 2016.

Supplementary material available online.